{"id":45870,"date":"2022-07-06T17:01:42","date_gmt":"2022-07-06T15:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/"},"modified":"2022-07-06T17:01:42","modified_gmt":"2022-07-06T15:01:42","slug":"u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/","title":{"rendered":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5336959\/hepatorenal-syndrome-treatment-market-research?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=hggbxk&amp;utm_campaign=1722423+-+U.S.+Hepatorenal+Syndrome+Treatment+Market+to+Reach+%242.29+Billion+by+2027+at+a+CAGR+of+14.78%25&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome), Treatment, End-User, State &#8211; United States Forecast to 2027 &#8211; Cumulative Impact of COVID-19&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe United States Hepatorenal Syndrome Treatment Market size was estimated at USD 1,004.79 million in 2021, USD 1,190.59 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.78% to reach USD 2,298.23 million by 2027.\n<\/p>\n<p>\n<strong>Market Segmentation &amp; Coverage:<\/strong>\n<\/p>\n<p>\nThis research report categorizes the Hepatorenal Syndrome Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:\n<\/p>\n<ul>\n<li>\nBased on Type, the market was studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.\n<\/li>\n<li>\nBased on Treatment, the market was studied across Surgical Treatment and Therapeutics.\n<\/li>\n<li>\nBased on End-User, the market was studied across Academic &amp; Research Institutes, Ambulatory Surgical Centers, and Hospitals &amp; Clinics.\n<\/li>\n<li>\nBased on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.\n<\/li>\n<\/ul>\n<p>\n<strong>Competitive Strategic Window:<\/strong>\n<\/p>\n<p>\nThe Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research &amp; development, and new product introduction strategies to execute further business expansion and growth during a forecast period.\n<\/p>\n<p>\n<strong>FPNV Positioning Matrix:<\/strong>\n<\/p>\n<p>\nThe FPNV Positioning Matrix evaluates and categorizes the vendors in the Hepatorenal Syndrome Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.\n<\/p>\n<p>\n<strong>Market Share Analysis:<\/strong>\n<\/p>\n<p>\nThe Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.\n<\/p>\n<p>\n<strong>Competitive Scenario:<\/strong>\n<\/p>\n<p>\nThe Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger &amp; Acquisition, Agreement, Collaboration, &amp; Partnership, New Product Launch &amp; Enhancement, Investment &amp; Funding, and Award, Recognition, &amp; Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor&#8217;s strength and weakness thereby, providing insights to enhance product and service.\n<\/p>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Preface<\/strong>\n<\/p>\n<p>\n<strong>2. Research Methodology<\/strong>\n<\/p>\n<p>\n<strong>3. Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>4. Market Overview<\/strong>\n<\/p>\n<p>\n<strong>5. Market Insights<\/strong>\n<\/p>\n<p>\n5.1. Market Dynamics\n<\/p>\n<p>\n5.1.1. Drivers\n<\/p>\n<p>\n5.1.2. Restraints\n<\/p>\n<p>\n5.1.3. Opportunities\n<\/p>\n<p>\n5.1.4. Challenges\n<\/p>\n<p>\n5.2. Cumulative Impact of COVID-19\n<\/p>\n<p>\n<strong>6. Hepatorenal Syndrome Treatment Market, by Type<\/strong>\n<\/p>\n<p>\n6.1. Introduction\n<\/p>\n<p>\n6.2. Type 1 Hepatorenal Syndrome\n<\/p>\n<p>\n6.3. Type 2 Hepatorenal Syndrome\n<\/p>\n<p>\n<strong>7. Hepatorenal Syndrome Treatment Market, by Treatment<\/strong>\n<\/p>\n<p>\n7.1. Introduction\n<\/p>\n<p>\n7.2. Surgical Treatment\n<\/p>\n<p>\n7.3. Therapeutics\n<\/p>\n<p>\n<strong>8. Hepatorenal Syndrome Treatment Market, by End-User<\/strong>\n<\/p>\n<p>\n8.1. Introduction\n<\/p>\n<p>\n8.2. Academic &amp; Research Institutes\n<\/p>\n<p>\n8.3. Ambulatory Surgical Centers\n<\/p>\n<p>\n8.4. Hospitals &amp; Clinics\n<\/p>\n<p>\n<strong>9. California Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>10. Florida Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>11. Illinois Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>12. New York Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>13. Ohio Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>14. Pennsylvania Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>15. Texas Hepatorenal Syndrome Treatment Market<\/strong>\n<\/p>\n<p>\n<strong>16. Competitive Landscape<\/strong>\n<\/p>\n<p>\n16.1. FPNV Positioning Matrix\n<\/p>\n<p>\n16.1.1. Quadrants\n<\/p>\n<p>\n16.1.2. Business Strategy\n<\/p>\n<p>\n16.1.3. Product Satisfaction\n<\/p>\n<p>\n16.2. Market Ranking Analysis\n<\/p>\n<p>\n16.3. Market Share Analysis, By Key Player\n<\/p>\n<p>\n16.4. Competitive Scenario\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAetna Inc.\n<\/li>\n<li>\nBaxter International Inc\n<\/li>\n<li>\nBecton, Dickinson and Company\n<\/li>\n<li>\nBioVie Inc\n<\/li>\n<li>\nCadila Healthcare Limited\n<\/li>\n<li>\nCumberland Pharmaceuticals Inc\n<\/li>\n<li>\nEdwards Lifesciences Corporation\n<\/li>\n<li>\nF. Hoffmann-La Roche AG\n<\/li>\n<li>\nFuji Systems Corp\n<\/li>\n<li>\nG Surgiwear Ltd\n<\/li>\n<li>\nGlaxoSmithKline plc\n<\/li>\n<li>\nJohnson &amp; Johnson Co\n<\/li>\n<li>\nLa Jolla Pharmaceutical Company\n<\/li>\n<li>\nLupin Limited\n<\/li>\n<li>\nMallinckrodt Inc\n<\/li>\n<li>\nMedtronic plc\n<\/li>\n<li>\nNeovii Pharmaceuticals AG\n<\/li>\n<li>\nNew Medicon Pharma Lab\n<\/li>\n<li>\nNoorik Biopharmaceuticals AG\n<\/li>\n<li>\nNovartis International AG\n<\/li>\n<li>\nOrphan Therapeutics, LLC\n<\/li>\n<li>\nPfizer Inc.\n<\/li>\n<li>\nPharmaIN Corporation\n<\/li>\n<li>\nSanofi S.A.\n<\/li>\n<li>\nThermo Fisher Scientific\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5336959\/hepatorenal-syndrome-treatment-market-research?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=hggbxk&amp;utm_campaign=1722423+-+U.S.+Hepatorenal+Syndrome+Treatment+Market+to+Reach+%242.29+Billion+by+2027+at+a+CAGR+of+14.78%25&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/9hx0wj<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#x72;&#101;s&#x73;&#64;r&#x65;&#x73;&#101;a&#x72;&#x63;&#104;a&#x6e;&#100;&#109;&#x61;&#x72;&#107;e&#x74;&#x73;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#101;&#115;&#101;&#97;&#114;chan&#x64;&#x6d;&#x61;&#x72;&#x6b;&#x65;&#x74;&#x73;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<p>\nFor E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome), Treatment, End-User, State &#8211; United States Forecast to 2027 &#8211; Cumulative Impact of COVID-19&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The United States Hepatorenal Syndrome Treatment Market size was estimated at USD 1,004.79 million in &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45870","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome), Treatment, End-User, State &#8211; United States Forecast to 2027 &#8211; Cumulative Impact of COVID-19&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The United States Hepatorenal Syndrome Treatment Market size was estimated at USD 1,004.79 million in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T15:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-06T15:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/\"},\"wordCount\":753,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005632\\\/en\\\/1506053\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/\",\"name\":\"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005632\\\/en\\\/1506053\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-06T15:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005632\\\/en\\\/1506053\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005632\\\/en\\\/1506053\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome), Treatment, End-User, State &#8211; United States Forecast to 2027 &#8211; Cumulative Impact of COVID-19&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The United States Hepatorenal Syndrome Treatment Market size was estimated at USD 1,004.79 million in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T15:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% &#8211; ResearchAndMarkets.com","datePublished":"2022-07-06T15:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/"},"wordCount":753,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/","name":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg","datePublished":"2022-07-06T15:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220706005632\/en\/1506053\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/u-s-hepatorenal-syndrome-treatment-market-to-reach-2-29-billion-by-2027-at-a-cagr-of-14-78-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"U.S. Hepatorenal Syndrome Treatment Market to Reach $2.29 Billion by 2027 at a CAGR of 14.78% &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45870"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45870\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}